surpass cvot tirzepatide results In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT trial results: https://nej.md/4qd5rLx Cardiovascular outcomes of semaglutide and

M.SorkinJ

Medical Contraindications to Discuss First GLP-1 medications carry a boxed warning regarding thyroid C-cell tumors in rodent models, and the FDA mandates that patients with a personal or family history of medullary thyroid carcinoma or MEN2 do not use these drugs [3]

The best results come when medical treatment is combined with balanced nutrition, resistance exercise, and attention to whole-person wellbeing

33 (8): 16851700.e9

Outcome (6 Months): At the 4-month mark, Mark reported a significant reduction in bloating and was able to reintroduce several foods without reaction

Shetty, R., Gupta, S., Ranade, R